-
J.P. Morgan Has A Note On Charles River Laboratories After Earnings (CRL)
Thursday, November 4, 2010 - 6:59am | 118J.P. Morgan Chase & Co. discusses Charles River Laboratories (NYSE: CRL) in a research report after the company reported earnings. It has a Neutral rating on shares and a $34 price target. In a note to clients, J.P. Morgan writes, "Bottom-line result due largely to share repurchase. Under the...
-
Cambrex Reports Third Quarter 2010 Results: Loss Per Share of $0.05
Wednesday, November 3, 2010 - 4:49pm | 162Cambrex Corporation (NYSE: CBM) reports third quarter results for the period ended September 30, 2010. Highlights * Reported sales decreased by 14.6%, and excluding the impact of foreign currency, sales decreased 11.5% compared to third quarter 2009. * Adjusted EBITDA was $8.5 million in the...
-
Covance Reports Third Quarter EPs of $(0.49)
Wednesday, November 3, 2010 - 4:27pm | 73Covance Inc. (NYSE: CVD) today reported results for its third quarter ended September 30, 2010, which included a GAAP loss of $0.49 per diluted share. Included in results is a $1.16 per diluted share non-cash impairment charge related to a write-down of preclinical assets, partially offset by a...
-
Parexel's 1QFY11 Helps Re-Set Outlook
Wednesday, November 3, 2010 - 7:42am | 136Goldman Sachs has published a research report on Parexel International Corporation (NASDAQ: PRXL) after the company reported solid new business win in its 1QFY11. In the report, Goldman Sachs writes "In addition to slower conversion, PRXL also revised its outlook to reflect changes in FX, client-...
-
Cambrex Acquires Stake in Zenara Pharma for $20M
Tuesday, November 2, 2010 - 4:51pm | 97Cambrex Corporation (NYSE: CBM) announced today that it acquired a 51% stake in Zenara Pharma, a Hyderabad, India based pharmaceutical company focused on the formulation of final dosage form products. Cambrex acquired a 51% equity stake in Zenara for $20 million, which may be adjusted based on...
-
Bearish MACD for Kendle Intl - Tale of the Tape
Tuesday, November 2, 2010 - 12:33pm | 117Kendle International Inc.'s (KNDL) MACD indicator has moved into bearish territory with a reading of -0.0404. The Zacks #4 Rank (“Sell”) stock decreased slightly to $8.97 in morning trade. The Zacks Consensus Estimate on the company's earnings for the year ending 2010 has decreased by a cent over...
-
Loss at MNKD Wider than Expected - Analyst Blog
Tuesday, November 2, 2010 - 11:00am | 510MannKind Corporation's (MNKD) third quarter 2010 net loss of 40 cents per share was wider than the Zacks Consensus Estimate of a loss of 39 cents. The company had suffered a loss of 42 cents per share in the year-ago quarter. The narrower year-over-year loss was attributable to lower expenses...
-
Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (HSP, ELN, NKTR, ALKS)
Tuesday, November 2, 2010 - 4:24am | 145Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of cash. Hospira Inc (NYSE: HSP) had $1.15 billion in total cash for the latest quarter. HSP's total debt stood at $2.24 billion in the same period. Elan Corporation Plc (NYSE: ELN) had $426.00 million in total cash and $1....
-
Balancing Election Results with Trading Ideas 11-01-2010
Monday, November 1, 2010 - 7:09pm | 1106Cusick' Corner The highly anticipated mid-term elections are tomorrow, so how can a trader or investor strategize the potential outcomes? If the election plays out as pundits anticipate, GOP takes the House and the Democrats maintain the Senate, we could see a short-term gridlock bounce and then...
-
Jefferies Remains Cautious On Vivus Pending Qnexa Approval
Monday, November 1, 2010 - 8:30am | 161Jefferies & Co. has published a research report on Vivus, Inc. (NASDAQ: VVUS) and is showing concern over the fact that the company has not yet obtained all the necessary data to combat the FDA's letter, focusing mainly on CV events. In the report, Jefferies writes "We remain concerned that...
-
Market Tricks or Treats 10-29-2010
Friday, October 29, 2010 - 5:55pm | 803Cusick's Corner Trick or Treat! No real action today – market participants were on the sidelines today, stuffing themselves with candy as they wait to see what Halloween costumes come knocking on the door next week. Traders are waiting on Tuesday's elections and the Fed's QE2 plan. Will it be a...
-
VIX on the Move Up 10-29-2010
Friday, October 29, 2010 - 2:46pm | 897Cusick's Corner The VIX is on the move up with the market going higher -- a potential flag that Tuesday's election hype and the Fed's QE2 seem to be already priced into the market. Headline risk can often be a potential catalyst for a higher VIX. Small Caps, IWM, and Finance, XLF (one of the 4...
-
AMAG Pharmaceuticals Hits 52-Week Low (AMAG)
Friday, October 29, 2010 - 10:55am | 272Shares of AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) are currently down 17.8% at $15.86 per share during Friday morning trading. Today's trading range for shares of AMAG Pharmaceuticals, Inc has been between a 52-week low of $15.13 and $16.60 per share. The consensus price target of analysts...
-
Benzinga's Top Pre-Market NASDAQ Losers (NUVA, AMAG, FSLR, CRXL)
Friday, October 29, 2010 - 8:40am | 143NuVasive Inc (NASDAQ: NUVA) dipped 25.98% to $27.10 in the pre-market session. NUVA lowered its projections for the full year. AMAG Pharmaceuticals Inc (NASDAQ: AMAG) lost 16.01% to $16.21 in the pre-market session. AMAG has announced its plans to reduce 24% of its workforce. First Solar Inc (...
-
J.P. Morgan Upgrades Vivus (VVUS)
Friday, October 29, 2010 - 7:31am | 181J.P. Morgan Chase & Co. upgraded VIVUS, Inc. (NASDAQ: VVUS) to Overweight from Neutral, and raised its price target to $13 from $6. In a note to clients, J.P. Morgan writes, "Late Thursday night VVUS announced that the FDA issued a Complete Response Letter (CRL) for Qnexa, as we were expecting...